Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced ovarian cancer, and altered the natural histo...

Full description

Bibliographic Details
Main Authors: Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Diagnostics
Subjects:
PARP inhibitors
ovarian cancer
<i>BRCA</i> mutations
homologous recombination deficiency
synthetic lethality
combination strategies
Online Access:https://www.mdpi.com/2075-4418/9/3/87

Internet

https://www.mdpi.com/2075-4418/9/3/87

Similar Items